Treat-to-target in systemic lupus erythematosus: Where are we today?

Clinical and Experimental Rheumatology

Volumn 30, Issue 4 SUPPL.73, 2012, Pages

  Mosca, M ^a   Boumpas, D ^b   Bruce, I N ^c   Cervera, R ^d   Czirjak, L ^e   Dorner T ^f   Houssiau, F ^g   Jacobsen, S ^h   Schneider, M ⁱ   Smolen, J S ^j   Voskuyl, A E ^k   Van Vollenhoven, R F ^l  

^a UNIVERSITY OF PISA   (Italy)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

^d HOSPITAL CLÍNIC   (Spain)

^e UNIVERSITY OF PÉCS   (Hungary)

^f CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^g CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^h Rigshospitalet   (Denmark)

ⁱ HEINRICH HEINE UNIVERSITY   (Germany)

^j MEDICAL UNIVERSITY OF VIENNA   (Austria)

^k ACADEMIC MEDICAL CENTER   (Netherlands)

^l KAROLINSKA INSTITUTE   (Sweden)

more..

Author keywords

Damage; Outcomes; Systemic lupus erythematosus; Treat to target

Indexed keywords

CORTICOSTEROID;

ARTICLE; COMORBIDITY; CORTICOSTEROID THERAPY; DISEASE ACTIVITY; DISEASE CONTROL; ECONOMIC ASPECT; FOLLOW UP; HUMAN; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; RECURRENT DISEASE; SERODIAGNOSIS; SYSTEMIC LUPUS ERYTHEMATOSUS;

DISEASE PROGRESSION; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; PATIENT CARE PLANNING; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 84870276669     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (56)

1. MAK A, CHEUNG M W L, CHIEW HJ, LIU YL, CHUNMAN H O R: Global trend of survival and damage of systemic lupus erythematosus: meta-analysis and meta-regression of observational studies from the 1950s to 2000s. Semin Arthitis Rheum 2012;41:830-49.
2. BERNATSKY S, BOIVIN JF, JOSEPH L et al.: Mortality in systemic lupus erythematosus. Arthritis Rheum 2006;54:2550-7.
3. GORDON C, BERTSIAS G, IOANNIDIS J P A et al.: EULAR points to consider for conducting clinical trials in systemic lupus erythematosus. Ann Rheum Dis 2009;68:470-6.
4. BERTSIAS G, IOANNIDIS J P A, BOLETIS J et al.: EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics. Ann Rheum Dis 2008;67:195-205.
5. MOSCA M, TANI C, ARINGER M et al.: European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies. Ann Rheum Dis 2010;69:1269-74.
6. STRAND V, GLADMAN D, ISENBERG D, PETRI M, SMOLEN J, TUGWELL P: Endpoints: consensus recommendations from OMERACT IV. Outcome Measures in Rheumatology. Lupus 2009;9:322-7.
7. YELIN E, TONNER C, TRUPIN L et al.: Longitudinal study of the impact of incident organ manifestations and increased disease activity on work loss among persons with systemic lupus erythematosus. Arthritis Care Res 2012;64:169-75.
8. MCELHONE K, JABBOTT J, TEH LS: A review of health related quality of life in systemic lupus erythematosus. Lupus 2006;15:633-43.
9. AGMON-LEVIN N, MOSCA M, PETRI M, SHOENFELD Y: Systemic lupus erythematosus one disease or many? Autoimmun Rev 2012;11:593-5.
10. TURCHETTI G, YAZDANY J, PALLA I, YELIN E, MOSCA M. Systemic lupus erythematosus and the economic perspective: a systematic literature review and points to consider. Clin Exp Rheumatol 2012;30(Suppl. 73):S116-S122.
11. MÖTTÖNEN T, HANNONEN P, LEIRISALOREPO M et al.: Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis:'a randomised trial. FIN-RACo trial group. Lancet 1999;353:1568-73.
12. GRIGOR C, CAPELL H, STIRLING A et al.: Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 2004;364:263-9.
13. VERSTAPPEN SM, JACOBS JW, VAN DER VEEN MJ et al.: Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial). Ann Rheum Dis 2007;66:1443-9.
14. HETLAND ML, STENGAARD-PEDERSEN K, JUNKER P et al.: Combination treatment with methotrexate, cyclosporine, and intraarticular betamethasone compared with methotrexate and intraarticular betamethasone in early active rheumatoid arthritis: an investigator-initiated, multicenter, randomized, double-blind, parallel-group, placebo-controlled study. Arthritis Rheum 2006;54:1401-9.
15. GOEKOOP-RUITERMAN YP, DE VRIES-BOUWSTRA JK, ALLAART CF et al.: Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum 2005;52:3381-90.
16. SMOLEN JS, ALETAHA D, BIJLSMA J et al.: Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010;69:631-37.
17. BARR SG, ZONANA-NACACH A, MADGER LS, PETRI M: Patterns of disease activity in systemic lupus erythematosus. Arthritis Rheum 1999;42:2682-8.
18. NIKPOUR M, UROWITZ MB, IBANEZ D, GLADMAN DD: Frequency and determinants of flare and persistently active disease in systemic lupus erythematosus. Arthritis Rheum 2009;61:1152-8.
19. ZEN M, BASSO N, NALOTTO L et al.: Disease activity patterns in a monocentric cohort of SLE patients: a seven-year follow-up study. Clin Exp Rheumatol 2012 Jul. 5. Epub ahead of print.
20. NOSSENT J, KISS E, ROZMAN B et al.: Disease activity and damage accrual during the early disease course in a multinational inception cohort of patients with systemic lupus erythematosus. Lupus 2010;19:949-56.
21. STEIMAN AJ, UROWITZ MB, IBANEZ D, PAPNEJA A, GLADMAN DD: Frequency and characteristics of prolonged remission in systemic lupus erythematosus. Arthritis Rheum 2011;63(Suppl. 10):1388.
22. VILA LM, ALARCON GS, MCGWIN G et al.: Early clinical manifestations, disease activity and damage of systemic lupus erythematosus among two distinct US Hispanic subpopulations. Rheumatology 2004;43:358-63.
23. ZONAN A, NACACH A BARR SG, MAGDER LS, PETRI M: Damage in systemic lupus erythematosus and its association with corticosteroids. Arthritis Rheum 2000;43:1801-5.
24. BEKER-MEROK A, NOSSENT HC: Damage accumulation in systemic lupus erythematosus and its relation to disease activity and mortality. J Rheumatol 2006;33:1570-88.
25. THAMER M, HERNAN MA, ZHANG Z, COTTER D, PETRI M: Prednisone, lupus activity and permanent organ damage. J Rheumatol 2009;36:560-4.
26. GLADMAN DD, UROWITZ MB, RAHMAN P, IBANEZ D, TAM LS: Accrual of organ damage over time in patients with systemic lupus erythematosus. J Rheumatol 2003;30:1955-9.
27. HOUSSIAU FA, VASCONCELOS C, D'CRUZ D et al.: Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis. Arthritis Rheum 2004;50:3934-40.
28. ARINGER M, STRAND V: Endpoints for randomised controlled trials in systemic lupus erythematosus. Clin Exp Rheumatol 2012;30:147-51.
29. ISENBERG DA, ALLEN E, FAREWELL V et al.: An assessment of disease flare in patients with systemic lupus erythematosus: a comparison of BILAG 2004 and the flare version of SELENA. Ann Rheum Dis 2011;70:54-9.
30. AMERICAN COLLEGE OF RHEUMATOLOGY AD HOC COMMITTEE ON SYSTEMIC LUPUS ERYTHEMATOSUS RESPONSE CRITERIA: The American College of Rheumatology response criteria for systemic lupus erythematosus clinical trials: measures of overall disease activity. Arthritis Rheum 2004;50:3418-26.
31. CHAMBERS SA, ALLEN E, RAHMAN A, ISENBERG D: Damage and mortality in a group of british patients with systemic lupus erythematosus followed up for over 10 years. Rheumatology 2009;48:673-5.
32. UROWITZ MB, GLADMAN DD, IBANEZ D et al.: Evolution of disease burden over five years in a multicenter inception systemic lupus erythematosus cohort. Arthritis Care Res 2012;64:132-7.
33. NIVED O, JONSEN A, BENGTSSON AA, BENGTSSON C, STURFELT G: High predictive value of the systemic lupus international collaborating clinics/American college of rheumatology damage index for survival in systemic lupus erythematosus. J Rheumatol 2002;29:1398-400.
34. NOSSENT J, CIKES N, KISS E et al.: Current causes of death in systemic lupus erythematosus in Europe, 2000-2004: relation to disease activity and damage accrual. Lupus 2007;16:309-17.
35. ALARCON GS, ROSEMAN JM, MCGWIN G Jr. et al.: Systemic lupus erythematosus in three ethnic groups. XX. Damage as a predictor of further damage. Rheumatology 2004;43:202-5.
36. URIBE AG, MCGWIN G JR, REVEILLE JD, ALARCON GS: What have we learned from a 10-year experience with the LUMINA (lupus in minorities; nature vs nurture) cohort? Where are we heading? Autoimm Rev 2004;3:321-9.
37. FAURSCHOU M, DREYER L, KAMPER AL, STARKLINT H, JACOBSEN S: Long-term mortality and renal outcome in a cohort of 100 patients with lupus nephritis. Arthritis Care Res 2010;62:873-80.
38. SYMMONS D P M, GABRIEL SE: Epidemiology of CVD in rheumatic disease, with a focus on RA and SLE. Nat Rev Rheumatol 2011;7:399-408.
39. KEELING SO, TEO M, FUNG D: Lack of cardiovascular risk assessment in inflammatory arthritis and systemic lupus erythematosus patients at a tertiary care center. Clin Rheumatol 2011;30:1311-7.
40. COSTENBADER KH, WRIGHT E, LIANG MH, KARLSON EW: Cardiac risk factor awareness and management in patients with systemic lupus erythematosus. Arthritis Rheum 2004;51:983-8.
41. SCHMAJUK G, YELIN E, CHAKRAVARTY E, NELSON LM, PANOPOLIS P, YAZDANY J: Osteoporosis screening, prevention, and treatment in systemic lupus erythematosus: application of the systemic lupus erythematosus quality indicators. Arthritis Care Res 2010;62:993-1001.
42. MOSCA M, TANI C, ARINGER M et al.: Development of quality indicators to evaluate the monitoring of SLE patients in routine clinical practice. Autoimmun Rev 2011;10:383-8.
43. ROVIN BH, ZHANG X: Biomarkers for lupus nephritis: the quest continues. Clin J Am Soc Nephrol 2009;4:1858-65.
44. STEINMAN AJ, GLADMAN DD, IBANEZ D, UROWITZ MB: Prolonged serologically active clinically quiescent systemic lupus erythematosus: frequency and outcome. J Rheumatol 2010;37:1822-7.
45. STEINMAN AJ, GLADMAN DD, IBANEZ D, UROWITZ MB: Outcomes in patients with systemic lupus erythematosus with and without a prolonged serologically active clinically quiescent period. J Rheumatol 2012;64:511-8.
46. YEN YC, FORTIN PR: Discordance between patients and their physicians in the assessment of lupus disease activity: relevance for clinical trials. Lupus 1999;8:660-70.
47. GALLOP K, NIXON A, SWINBURN P, STERLING KL, NAEGELI AN, SILK ME: Development of a conceptual model of health-related quality of life for systemic lupus erythematosus (SLE) from the patients' perspective. Lupus 2012;21:934-43.
48. ROBINSON D, AGUILAR D, SCHOENWETTER M et al.: Impact of systemic lupus erythematosus on health, family, and work: the patient perspective. Arthritis Care Res 2010;2:266-73.
49. CLEANTHOUS S, TYAGI M, ISENBERG DA, NEWMAN SP: What do we know about self-reported fatigue in systemic lupus erythematosus? Lupus 2012;21:465-76.
50. YELIN E, TRUPIN L, KATZ P et al.: Work dynamics among persons with systemic lupus erythematosus. Arthritis Care Res 2007;57:56-63.
51. TURCHETTI G, SCALONE L, DELLA CASA ALBERIGHI O et al.: The rationale of pharmacoeconomic analysis in rheumatologic indications. Clin Exp Rheumatol 2012;30(Suppl. 73):S64-S71.
52. FURNERI G, MANTOVANI LG, BELISARI A et al.: Systematic literature review on economic implications and pharmacoeconomic issues of rheumatoid arthritis. Clin Exp Rheumatol 2012;30(Suppl. 73):S72-S84.
53. CORTESI PA, SCALONE L, D'ANGIOLELLA L et al.: Systematic literature review on economic implications and pharmacoeconomic issues of psoriatic arthritis. Clin Exp Rheumatol 2012;30(Suppl. 73):S126-S131.
54. TRIESTE L, PALLA I, BALDINI C et al.: Systemic vasculitis: how little we know about their societal and economic burden. Clin Exp Rheumatol 2012;30(Suppl. 73):S154-S156.
55. TRIESTE L, PALLA I, FUSCO F et al.: The economic impact of gout: systematic literature review. Clin Exp Rheumatol 2012;30(Suppl. 73):S145-S148.
56. PALLA I, TRIESTE L, TANI C et al.: A systematic literature review of the economic impact of ankylosing spondylitis. Clin Exp Rheumatol 2012;30(Suppl. 73):S136-S141.